- Home
- PGRE vs ELVN Comparison
PGRE vs ELVN Comparison
Compare PGRE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- ELVN
- Stock Information
- Founded
- PGRE 1978
- ELVN 2016
- Country
- PGRE United States
- ELVN United States
- Employees
- PGRE N/A
- ELVN N/A
- Industry
- PGRE Real Estate Investment Trusts
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- ELVN Health Care
- Exchange
- PGRE Nasdaq
- ELVN Nasdaq
- Market Cap
- PGRE 1.0B
- ELVN 1.1B
- IPO Year
- PGRE 2014
- ELVN 2020
- Fundamental
- Price
- PGRE $4.80
- ELVN $22.47
- Analyst Decision
- PGRE Hold
- ELVN Strong Buy
- Analyst Count
- PGRE 3
- ELVN 5
- Target Price
- PGRE $4.50
- ELVN $37.80
- AVG Volume (30 Days)
- PGRE 1.0M
- ELVN 204.7K
- Earning Date
- PGRE 02-12-2025
- ELVN 11-13-2024
- Dividend Yield
- PGRE 2.18%
- ELVN N/A
- EPS Growth
- PGRE N/A
- ELVN N/A
- EPS
- PGRE N/A
- ELVN N/A
- Revenue
- PGRE $553,641,000.00
- ELVN N/A
- Revenue This Year
- PGRE N/A
- ELVN N/A
- Revenue Next Year
- PGRE N/A
- ELVN N/A
- P/E Ratio
- PGRE N/A
- ELVN N/A
- Revenue Growth
- PGRE N/A
- ELVN N/A
- 52 Week Low
- PGRE $4.21
- ELVN $10.90
- 52 Week High
- PGRE $5.47
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- PGRE 46.84
- ELVN 39.53
- Support Level
- PGRE $4.80
- ELVN $21.84
- Resistance Level
- PGRE $4.97
- ELVN $24.42
- Average True Range (ATR)
- PGRE 0.16
- ELVN 1.59
- MACD
- PGRE -0.01
- ELVN -0.05
- Stochastic Oscillator
- PGRE 45.45
- ELVN 18.27
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. Paramount Group derives nearly all of its revenue in the form of rental income from leasing its offices to tenants.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.